Main Menu

Our Work

United States v. Novartis Pharmaceuticals Corp. and BioScrip, Inc.

In United States v. Novartis Pharmaceuticals Corp. and BioScrip, Inc., provided expert testimony for Novartis on the economics of pharmacy dispensing, government reimbursements, and adherence in connection with alleged FCA violations associated with alleged kickbacks concerning Novartis’s distribution of two specialty brand-name pharmaceuticals: Myfortic and Exjade.

Jump to Page